← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicMonika Joshi, MDviaPhase 3

Eribulin mesylate (Eribulin mesylate)

Metastatic Urothelial Cell Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 71.2%임상시험 59상태 RECRUITING
ADCBiologicSWOG Cancer Research NetworkDM1) and/or trastuzumab der…Phase 3

HER2-targeted Therapy (HER2-targeted Therapy)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 18.75%임상시험 59상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCsPhase 2

Hyaluronidase (Hyaluronidase)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 64.3%임상시험 59상태 DISCONTINUED
CGTBiologicMerck Sharp & Dohme LLCPhase 2

Interferon-alpha (Interferon-alpha)

Lymphoproliferative Disorder; HHV-8 · Lymphoproliferative Disorder

#LymphoproliferativeDisorder#CGT#Phase2#인기#세포유전치료+5
임상시험 59상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab and nivolumab)

Mesothelioma; Pancreatic Cancer · Uveal Melanoma, Metastatic

#UvealMelanomaMetastatic#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 59상태 RECRUITING
ADCBiologicNYU Langone HealthPhase 2

Leflunomide (Leflunomide)

Rheumatic Disease · Takayasu Arteritis

#TakayasuArteritis#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 6.35%임상시험 59상태 RECRUITING
CGTBiologicImmunityBio, Inc.sPhase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+4
임상시험 59상태 DISCONTINUED
CGTBiologicBinhui Biopharmaceutical Co., L…Phase 1

IDOV-SAFETM (Oncolytic Virus injection, Oncolytic Virus injection(IDOV-SAFETM))

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase1#인기#세포유전치료+4
효능 ORR 28%임상시험 59상태 RECRUITING
CGTBiologicInge Marie SvanePhase 1

Proleukin (Proleukin)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#인기#세포유전치료+5
효능 ORR 33.3%임상시험 59상태 RECRUITING
CGTBiologicSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32.4%임상시험 59상태 ACTIVE
ADCBiologicGenzyme, a Sanofi Companyvedotin-based regimens in C…Phase 2

Reduced Intensity Conditioning (Reduced Intensity Conditioning)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 2%임상시험 59상태 ACTIVE
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Advanced Breast Cancer; Objective Response Rate · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 59상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Vismodegib (Vismodegib)

Cancer of Unknown Primary Site · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 88%임상시험 59상태 DISCONTINUED
CGTBiologicSMT bio Co., Ltd.Phase 2

allogeneic Natural Killer cell ('SMT-NK' Inj, 'SMT-NK' Inj (allogeneic Natural Killer cell))

Biliary Tract Cancer · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase2#인기#세포유전치료+4
효능 ORR 42%임상시험 58상태 ACTIVE
CGTAAVBiologicBayerPhase 1

AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV, AAVrh.10hFXN, serotype rh.10 adeno-associated virus, AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN)

Friedreich Ataxia; Cardiomyopathies · Friedreich Ataxia

#FriedreichAtaxia#CGT#Phase1#인기#세포유전치료+5
효능 ORR 11.9%임상시험 58상태 RECRUITING
CGTBiologicPaolo Caimi, MDPhase 1

Allogeneic NK cells (Allogeneic NK cells)

Non Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#인기#세포유전치료+4
효능 ORR 5%임상시험 58상태 RECRUITING
ADCBiologicFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 86%임상시험 58상태 RECRUITING
ADCBiologicJanssen Research & Development,…Phase 1

Apalutamide (Apalutamide)

Prostatic Neoplasms · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 2.6%임상시험 58상태 RECRUITING
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma

#ResectableHepatocellularCarcinom#Antibody#Phase2#인기#항체+5
효능 ORR 50%임상시험 58상태 DISCONTINUED
AntibodyNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#인기#항체+4
효능 ORR 10%임상시험 58상태 ACTIVE

17 / 209 페이지

← 이전다음 →